Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | OGA | O60502 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27571753 | 0.85 | CYP2D6 (0.71) | ALDH1A1CYP2D6MC4RCHRM1CHRM2 | |
| SCHEMBL211238 | 0.82 | CYP3A4 (0.52) | ALDH1A1CYP2D6 | |
| SCHEMBL27666937 | 0.81 | ALDH1A1 (0.51) | ALDH1A1CYP2D6MC4RCHRM1CHRM2 | |
| SCHEMBL27666938 | 0.81 | ALDH1A1 (0.51) | ALDH1A1CYP2D6MC4RCHRM1CHRM2 | |
| SCHEMBL25171539 | 0.81 | ALDH1A1 (0.51) | ALDH1A1CYP2D6MC4RCHRM1CHRM2 | |
| SCHEMBL25171538 | 0.81 | ALDH1A1 (0.51) | ALDH1A1CYP2D6MC4RCHRM1CHRM2 | |
| SCHEMBL672150 | 0.81 | ALDH1A1 (0.51) | ALDH1A1CYP2D6MC4RCHRM1CHRM2 | |
| SCHEMBL209672 | 0.80 | GPR119 (0.49) | ALDH1A1CHRM1CHRM2HRH3 | |
| SCHEMBL19005178 | 0.80 | OGA (0.45) | ALDH1A1CYP2D6OGA | |
| SCHEMBL13600067 | 0.80 | POLB (0.57) | ALDH1A1CYP2D6KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963315-B1 | ENZYME INHIBITORS | CANCER REC TECH LTD (GB) | 2014-10-08 | — | — | EP | disclosed |
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
| EP-1963315-A2 | ENZYME INHIBITORS | The Institute of Cancer Research (GB) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007072017-A2 | ENZYME INHIBITORS | THE INSTITUTE OF CANCER RESEARCH (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | ALDH1A1 3015/4885CYP2D6 1028/4885MC4R 4750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.